Silver Book Fact

Multifoca electroretinogram (mFERG) measures show abnormal function of the retina early in–and even prior to–diabetic retinopathy onset and could enhance monitoring of the early stages of disease progression in individuals.

Bearse, Marcus A., Anthony J. Adams, Ying Han, Marilyn E. Schneck, Jason Ng, Kevin Bronson-Castain, and Shirin Barez. A Mulifocal Electroretinogram Model Predicting the Development of Diabetic Retinopathy. Prog Retin Eye Res. 2006; 25(5): 425-448. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773701/

Reference

Title
A Mulifocal Electroretinogram Model Predicting the Development of Diabetic Retinopathy
Publication
Prog Retin Eye Res
Publication Date
2006
Authors
Bearse, Marcus A., Anthony J. Adams, Ying Han, Marilyn E. Schneck, Jason Ng, Kevin Bronson-Castain, and Shirin Barez
Volume & Issue
Volume 25, Issue 5
Pages
425-448
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • The prevalence of age-related macular degeneration (AMD) in the 40 and older population has decreased from an estimated 9.4% from 1988 to 1994, to 6.5% for 2005 to 2008.  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of over $472.1 million– in 1994 dollars.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • The ACCORD Eye Study found that combination lipid therapy with a fibrate and statin (compared with statin treatment alone) reduced progression of diabetic retinopathy in type 2 diabetics by around…